On Health Policy Archives

NCHR Testimony at the FDA Listening Session on Advisory Committee Meetings

June 13, 2024: NCHR testified at the FDA listening session on Advisory Committee reform. We expressed concerns with the miscategorization of Consumer Representatives on AdComs and the ability of individuals with prior financial ties to industry to serve on these committees.

The Patient, Consumer, and Public Health Coalition Testified at an FDA Listening Session on Advisory Committees

June 13, 2024: The Patient, Consumer, and Public Health coalition testified at the FDA listening session on Advisory Committee reform. We expressed concerns with the miscategorization of Consumer Representatives on AdComs, the inherent conflicts of interests of committee members, and inadequate training provided to appointees.

NCHR’s Public Comment on Early Alzheimer’s Disease: Developing Drugs for Treatment; Draft Guidance for Industry

June 10, 2024: NCHR disagrees with assumptions made in FDA guidance aimed at developing drugs for treatment of early stages of Alzheimer’s dementia.

NCHR Comment on Proposed Information Collection Request; Comment Request; POTW Influent PFAS Study Data Collection

May 28, 2024: NCHR supports the EPA’s proposed plan to collect data on PFAS contaminants in public water sources but urges EPA to protect public health by expanding the plan to test for many more PFAS chemicals and at more testing plants.

NCHR Testifies at the Pediatric Oncology Subcommittee Meeting

May 22, 2024: NCHR provided public testimony at the pediatric oncology subcommittee meeting regarding Section 504 of the 2017 FDA Reauthorization Act. We expressed concern that efforts to increase availability of new treatments for pediatric cancer have resulted in more planned studies but not in more treatments. We recommended sponsors prioritize engaging with key stakeholders such as the EMA Paediatric Committee, FDA Pediatric Review Committee, FDA Oncology Subcommittee of the Pediatric Review Committee, the Oncology Center of Excellence, and the use of independent Pediatric Expert Groups.